Benchmarking Utility Clean Energy Deployment: 2016

Benchmarking Utility Clean Energy Deployment: 2016 provides a window into how the global transition toward clean energy is playing out in the U.S. electric power sector. Specifically, it reveals the extent to which 30 of the largest U.S. investor-owned electric utility holding companies are increasingly deploying clean energy resources to meet customer needs.Benchmarking these companies provides an opportunity for transparent reporting and analysis of important industry trends. It fills a knowledge gap by offering utilities, regulators, investors, policymakers and other stakeholders consistent and comparable information on which to base their decisions. And it provides perspective on which utilities are best positioned in a shifting policy landscape, including likely implementation of the U.S. EPA's Clean Power Plan aimed at reducing carbon pollution from power plants

Accelerating U.S. Clean Energy Deployment: Investor Policy Priorities

International investment to mitigate climate change is far below levels needed to reach the two-degree target. The International Energy Agency estimates that an average of an additional $1 trillion in incremental financing for clean energy is needed to meet the temperature target. In September 2014, over 350 investors representing$24 trillion in assets issued the Global Investor Statement on Climate Change, calling on governments to create an ambitious global agreement that includes a meaningful price on carbon -- the "Clean Trillion."This paper connects the Clean Trillion goal to the current United States climate and clean energy policy framework, which is a mixture of federal, state, and local initiatives. The paper outlines the 2015 U.S. policy priorities of the Policy Working Group of the Investor Network on Climate Risk (INCR), a network of more than 110 institutional investors primarily based in the U.S., focused on investment risks and opportunities associated with climate change

The association between meteorological events and acute heart failure: New insights from ASCEND-HF

Introduction Given the rising prevalence of heart failure (HF), our objective is to explore the relationships between meteorological events and acute HF (AHF) globally. Methods We used data from 30 countries participating in the ASCEND-HF trial. Parameters including temperature were normalized by location for the 37 days prior to the HF event. Meteorological events were classified as a change that occurred < 10% compared to baseline. The 7 days prior to the HF event was subdivided: T1: the day of and − 1 day; T2: 2 and 3 days; T3: 4 and 5 days; and T4: 6 and 7 days. Results are reported as ratios of observed to expected weather events at the time of AHF presentation. Results From 7141 patients, median age was 67 (IQR 56–76) with 66% male patients and 60% of patients with ischemic cardiomyopathy. In T1, temperatures were warmer than expected with 10% fewer decreases in average [OR 0.91 95% CI (0.83–0.98)] and minimum [OR 0.90 95% CI (0.82–0.97)] temperature. In T2, temperatures were again warmer than expected with an excess number of increases in maximum [OR 1.18 95% CI (1.06–1.30)] and average [OR 1.21 95% CI (1.10–1.32)] temperature. In T4 temperatures were cooler than baseline with fewer increases [OR 0.84 95% CI (0.74–0.95)] in average temperature. Conclusions Meteorological fluctuations appear most relevant in the 3 days (T1 and T2) prior to the HF hospitalization with temperature demonstrating a bidirectional relationship with AHF. Continued validation of biometeorological trends in HF will contribute to healthcare system planning globally

Gut microbiota modulation with long-chain corn bran arabinoxylan in adults with overweight and obesity is linked to an individualized temporal increase in fecal propionate.

BACKGROUND: Variability in the health effects of dietary fiber might arise from inter-individual differences in the gut microbiota's ability to ferment these substrates into beneficial metabolites. Our understanding of what drives this individuality is vastly incomplete and will require an ecological perspective as microbiomes function as complex inter-connected communities. Here, we performed a parallel two-arm, exploratory randomized controlled trial in 31 adults with overweight and class-I obesity to characterize the effects of long-chain, complex arabinoxylan (n = 15) at high supplementation doses (female: 25 g/day; male: 35 g/day) on gut microbiota composition and short-chain fatty acid production as compared to microcrystalline cellulose (n = 16, non-fermentable control), and integrated the findings using an ecological framework. RESULTS: Arabinoxylan resulted in a global shift in fecal bacterial community composition, reduced α-diversity, and the promotion of specific taxa, including operational taxonomic units related to Bifidobacterium longum, Blautia obeum, and Prevotella copri. Arabinoxylan further increased fecal propionate concentrations (p = 0.012, Friedman's test), an effect that showed two distinct groupings of temporal responses in participants. The two groups showed differences in compositional shifts of the microbiota (p ≤ 0.025, PERMANOVA), and multiple linear regression (MLR) analyses revealed that the propionate response was predictable through shifts and, to a lesser degree, baseline composition of the microbiota. Principal components (PCs) derived from community data were better predictors in MLR models as compared to single taxa, indicating that arabinoxylan fermentation is the result of multi-species interactions within microbiomes. CONCLUSION: This study showed that long-chain arabinoxylan modulates both microbiota composition and the output of health-relevant SCFAs, providing information for a more targeted application of this fiber. Variation in propionate production was linked to both compositional shifts and baseline composition, with PCs derived from shifts of the global microbial community showing the strongest associations. These findings constitute a proof-of-concept for the merit of an ecological framework that considers features of the wider gut microbial community for the prediction of metabolic outcomes of dietary fiber fermentation. This provides a basis to personalize the use of dietary fiber in nutritional application and to stratify human populations by relevant gut microbiota features to account for the inconsistent health effects in human intervention studies. TRIAL REGISTRATION: Clinicaltrials.gov, NCT02322112 , registered on July 3, 2015. Video Abstract

Elucidating the role of the gut microbiota in the physiological effects of dietary fiber.

Dietary fiber is an integral part of a healthy diet, but questions remain about the mechanisms that underlie effects and the causal contributions of the gut microbiota. Here, we performed a 6-week exploratory trial in adults with excess weight (BMI: 25-35 kg/m) to compare the effects of a high-dose (females: 25 g/day; males: 35 g/day) supplement of fermentable corn bran arabinoxylan (AX; n = 15) with that of microbiota-non-accessible microcrystalline cellulose (MCC; n = 16). Obesity-related surrogate endpoints and biomarkers of host-microbiome interactions implicated in the pathophysiology of obesity (trimethylamine N-oxide, gut hormones, cytokines, and measures of intestinal barrier integrity) were assessed. We then determined whether clinical outcomes could be predicted by fecal microbiota features or mechanistic biomarkers. AX enhanced satiety after a meal and decreased homeostatic model assessment of insulin resistance (HOMA-IR), while MCC reduced tumor necrosis factor-α and fecal calprotectin. Machine learning models determined that effects on satiety could be predicted by fecal bacterial taxa that utilized AX, as identified by bioorthogonal non-canonical amino acid tagging. Reductions in HOMA-IR and calprotectin were associated with shifts in fecal bile acids, but correlations were negative, suggesting that the benefits of fiber may not be mediated by their effects on bile acid pools. Biomarkers of host-microbiome interactions often linked to bacterial metabolites derived from fiber fermentation (short-chain fatty acids) were not affected by AX supplementation when compared to non-accessible MCC. This study demonstrates the efficacy of purified dietary fibers when used as supplements and suggests that satietogenic effects of AX may be linked to bacterial taxa that ferment the fiber or utilize breakdown products. Other effects are likely microbiome independent. The findings provide a basis for fiber-type specific therapeutic applications and their personalization. Clinicaltrials.gov, NCT02322112 , registered on July 3, 2015. Video Abstract